The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) reached all time high today, Oct, 4 and still has $45.53 target or 163.00% above today’s $17.31 share price. This indicates more upside for the $106.37 million company. This technical setup was reported by Barchart.com. If the $45.53 PT is reached, the company will be worth $173.38M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 2.61M shares traded hands or 6337.93% up from the average. Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has risen 31.06% since March 1, 2016 and is uptrending. It has outperformed by 21.82% the S&P500.
Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Ratings Coverage
Out of 3 analysts covering Summit Therapeutic (NASDAQ:SMMT), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $28 is the highest target while $26 is the lowest. The $27 average target is 55.98% above today’s ($17.31) stock price. Summit Therapeutic has been the topic of 4 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has “Buy” rating given on Wednesday, August 19 by Oppenheimer. As per Tuesday, September 1, the company rating was downgraded by Zacks. The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) earned “Buy” rating by H.C. Wainwright on Friday, September 16. The rating was initiated by Janney Capital on Tuesday, June 21 with “Buy”.
According to Zacks Investment Research, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.”
More notable recent Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) news were published by: Schaeffersresearch.com which released: “Buzz Stocks: Apple Inc., Aralez Pharmaceuticals Inc, and Summit Therapeutics …” on October 04, 2016, also Marketwatch.com with their article: “Summit Therapeutics PLC ADR” published on April 22, 2011, Schaeffersresearch.com published: “Biotech Buzz: Axovant Sciences Ltd, Summit Therapeutics PLC (ADR), and Mylan NV” on September 26, 2016. More interesting news about Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) were released by: Quotes.Wsj.com and their article: “DOW JONES, A NEWS CORP COMPANY” published on February 13, 2011 as well as Businessfinancenews.com‘s news article titled: “Summit Therapeutics Receives Phase 2 Trial Approval for DMD Patients” with publication date: January 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.